Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+ Breast Cancer.
Eric M LanderKatherine C RappazzoLi-Ching HuangJiun-Ruey HuHeidi ChenYu ShyrVandana G AbramsonPublished in: The oncologist (2023)
These data found a positive association between the HER2/CEP17 FISH ratio and pCR following neoadjuvant dual HER2-targeted therapy without chemotherapy. Larger prospective studies are needed to validate the HER2 ratio as a biomarker to select patients for neoadjuvant dual anti-HER2 therapy without chemotherapy.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- radiation therapy
- lymph node
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- electronic health record
- mesenchymal stem cells
- patient reported outcomes
- bone marrow
- deep learning
- patient reported
- chemotherapy induced
- smoking cessation